


DiagnaMed Announces BRAIN AGE® Trademark Registration Approved by CIPO

BRAIN AGE® solution is part of the CERVAI™ Brain Health AI Platform

TORONTO, March 20, 2024 -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), an artificial intelligence digital healthcare company, announced its application for registration for trademark on its BRAIN AGE® brand has been approved by the Canadian Intellectual Property Office (CIPO), particularly for commercial use throughout Canada for the goods and services for which it is registered as a neurological monitoring apparatus, electroencephalogram-based apparatus, and brain monitoring apparatus.

The Company continues to expand its commercial initiatives in Canada for its CERVAI™ Brain Health AI Platform, which includes the BRAIN AGE® estimation solution, and is part of the Hamilton Ecosystem to Accelerate and Leverage Trials of Health Innovation (HEALTHI) program in assisting the Company in developing relationships with world-class clinicians and hospital facilities in Canada’s leading research hospitals, such as Hamilton Health Sciences and St. Joe’s Healthcare Hamilton.

The CERVAI™ Brain Health commercial pilot program is available to clinics in Canada and the U.S. Ideal clinics for the pilot program must focus on health and wellness, sports and physical therapy, mental health, chiropractic care, or clinical research for neurological and cognitive disorders. For more information about CERVAI™ and joining the pilot program, visit <https://www.diagnamed.com/hcpartner>.





The graphic features a central orange background with rounded corners. On the left is an image of the CERVAI™ Brain Health device, a black head-mounted EEG cap with multiple sensors. In the center, the text 'CERVAI™ Brain Health' is displayed in a bold, black, sans-serif font. To the right is a photograph of a person sitting at a desk, viewed from behind, looking at a computer monitor displaying data. Below the central text are two white rounded rectangular boxes. The left box contains a bulleted list of features: 'Estimating BRAIN AGE®', 'Providing Brain Health Risk Score', 'Monitoring Overall Brain Health', and 'Use in Clinic and Home'. The right box is titled 'Validation studies performed' and contains the logos for Drexel University (a yellow dragon on a blue square) and the University of Miami (an orange and green 'U' above the word 'MIAMI'). At the bottom right corner of the orange background is the DiagnaMed logo, which consists of a stylized brain icon and the text 'DiagnaMed'.

CERVAI™
Brain Health

- Estimating BRAIN AGE®
- Providing Brain Health Risk Score
- Monitoring Overall Brain Health
- Use in Clinic and Home

Validation studies performed

DiagnaMed

CERVAI™ Brain Health AI Platform is a world-first consumer brain health and wellness AI solution that estimates BRAIN AGE® and provides a brain health score. Based on research and development at Drexel University and the University of Miami, CERVAI™ combines a BRAIN AGE® Estimation and Brain Health Assessment tool with the aim to ‘raise a red flag’ for potential brain health issues. CERVAI™ can assess if a brain is aging more quickly or more slowly than is typical for healthy individuals. Brain age is estimated by collecting neural activity data of the brain with a low-cost and easy-to-use electroencephalogram (“EEG”) headset and calculating the data with a proprietary machine-learning model. In addition, CERVAI™ can assess if a person has a healthy brain or is in the early stage of cognitive decline. Brain health is scored by taking a clinically validated assessment for brain resilience, vulnerability and performance functions. Individuals can seek out personalized diagnostics and interventions, such as medication or lifestyle changes, that may help to decrease the development or progression of cognitive decline.

About DiagnaMed

DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) is an artificial intelligence digital healthcare company focused on commercializing CERVAI™, a world-first consumer brain health and wellness AI solution that estimates BRAIN AGE® and provides a brain health score. Visit DiagnaMed.com.

For more information, please contact:

Fabio Chianelli
Chairman and CEO
DiagnaMed Holdings Corp.
Tel: 416-800-2684
Email: info@diagnamed.com
Website: www.diagnamed.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accepted responsibility for the adequacy or accuracy of this release.

Cautionary Statement

Certain statements in this news release are forward-looking statements, including with respect to future plans, and other matters. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such information can generally be identified by the use of forwarding-looking wording such as “will”, “may”, “expect”, “could”, “can”, “estimate”, “anticipate”, “intend”, “believe”, “aims”, and “continue” or the negative thereof or similar variations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including but not limited to, business, economic and capital market conditions,

the ability to manage operating expenses, and dependence on key personnel. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, anticipated costs, and the ability to achieve goals. Factors that could cause the actual results to differ materially from those in forward-looking statements include, the continued availability of capital and financing, litigation, failure of counterparties to perform their contractual obligations, loss of key employees and consultants, and general economic, market or business conditions. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in Company’s management’s discussion and analysis for the three months ended December 31, 2023 (“MD&A”), dated February 29, 2024, which is available on the Company's profile at www.sedarplus.ca. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The reader is cautioned not to place undue reliance on any forward-looking information. The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.